Abstract
Alzheimer’s disease (AD) and AD-related dementias (ADRD) exhibit heterogeneous progression rates, with rapid progression (RP) posing significant challenges for timely intervention and treatment. The increasingly available patient-centered electronic health records (EHRs) have made it possible to develop advanced machine learning models for risk prediction of disease progression by leveraging comprehensive clinical, demographic, and laboratory data. In this study, we propose AutoRADP, an interpretable autoencoder-based framework that predicts rapid AD/ADRD progression using both structured and unstructured EHR data from UFHealth. AutoRADP incorporates a rule-based natural language processing method to extract critical cognitive assessments from clinical notes, combined with feature selection techniques to identify essential structured EHR features. To address the data imbalance issue, we implement a hybrid sampling strategy that combines similarity-based and clustering-based upsampling. Additionally, by utilizing SHapley Additive exPlanations (SHAP) values, we provide interpretable predictions, shedding light on the key factors driving the rapid progression of AD/ADRD. We demonstrate that AutoRADP outperforms existing methods, highlighting the potential of our framework to advance precision medicine by enabling accurate and interpretable predictions of rapid AD/ADRD progression, and thereby supporting improved clinical decision-making and personalized interventions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
We acknowledge the University of Florida Integrated Data Repository (IDR) and the UF Health Office of the Chief Data Officer for providing the analytic data set for this project. Additionally, the Research reported in this publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under University of Florida Clinical and Translational Science Awards UL1TR000064 and UL1TR001427.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the University of Florida Institutional Review Board (IRB) under protocol no. IRB202001888.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data is private, which will be not released to the public.
